By Judy Carmody, Ph.D., Carmody Quality Solutions, LLC Happy Holidays! My hope is that you are on a couch or in a comfy chair sipping hot chocolate or some other holiday beverage as you read this. As always, now is the time — when one year ends and another begins — to reflect back and…
At a workshop … the organizer gave us an exercise tied to new requirements from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) E6(R2) — study risks versus system risks. … Many individuals sat with dazed looks, in a dull panic, not sure where to begin.
When he was home for the holidays, my 23-year-old son and I had intense, heated discussions about generational differences. We are still on speaking terms, but it got me thinking about how well we understand and value young people…
An article examining recent GMP inspection data from two prominent regulatory bodies notes that “Deficiencies in investigations remains at the top of this list over the past four years. We as an industry cannot seem to get this quite right.” I agree. Here’s why.
![How To Optimize Your Stability Program At Each Phase Of Drug Development [Checklists Included]](https://carmodyqs.com/wp-content/uploads/2017/04/biopinline-e1695317859166.png)
A well-managed stability program with thoughtfully constructed protocols demonstrates your lab and quality systems are in control.
… of the 40 GMP warning letters issued by FDA for data integrity deficiencies in 2015, 12 (30%) referenced training issues or requirements.
The U.S. Food and Drug Administration (FDA) cites corporate culture as a root cause of many compliance issues. It also says a strong quality culture “can lead to sustainable compliance.”
